| 摘要 |
<p>The invention relates to novel dioxaheterocyclic compounds of the formula I <IMAGE> (I) in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic radical or an unsubstituted or lower alkylated, mono- or bi-cyclic cycloaliphatic hydrocarbon radical or an alpha -branched aliphatic hydrocarbon radical, each of R2 and R3, independently of the other, represents hydrogen or lower alkyl, and each of R4 and R5, independently of the other, represents hydrogen, lower alkyl or halogen, and A represents the radical -O-R6, wherein R6 represents hydrogen or an unsubstituted or substituted aliphatic or araliphatic hydrocarbon radical or A represents the radical <IMAGE> in which each of R7 and R8, independently of the other, represents hydrogen or lower alkyl, or R7 and R8 are bonded to one another and, together with the adjacent nitrogen atom, represent unsubstituted or lower alkyl-substituted tetra- to hexa-methyleneimino or 4-morpholinyl, and the divalent radical in formula I is either in the 4,5- or the 5,6-position and correspondingly R4 and R5 are in positions 6 and 7, or 4 and 7, respectively, of the benzodioxole skeleton, to salts of compounds of the formula I in which A represents OR6 wherein R6 represents hydrogen, with bases, as well as acid addition salts of compounds of the formula I in which the radical R1 is of basic character, and to pharmaceutical compositions containing them. These novel substances have a diuretic activity and, in addition, a uricosuric activity, and can be administered, according to the invention, preferably in the form of corresponding pharmaceutical compositions, to mammals for the treatment of oedema and hypertension.</p> |
